Primary sclerosing cholangitis: Diagnosis, prognosis, and management

Clinical Gastroenterology and Hepatology

Volumn 11, Issue 8, 2013, Pages 898-907

  Singh, Siddharth ^a   Talwalkar, Jayant A ^a  

^a MAYO CLINIC   (United States)

Author keywords

Primary sclerosing cholangitis (PSC)

Indexed keywords

AZATHIOPRINE; BISPHOSPHONIC ACID DERIVATIVE; BUDESONIDE; CALCIUM; CHENODEOXYCHOLIC ACID; COLCHICINE; CYCLOSPORIN; ETANERCEPT; GABAPENTIN; INFLIXIMAB; METHOTREXATE; METRONIDAZOLE; MINOCYCLINE; MYCOPHENOLIC ACID; NALTREXONE; PENICILLAMINE; PENTOXIFYLLINE; PIRFENIDONE; PREDNISOLONE; RIFAMPICIN; SERTRALINE; SILYMARIN; TACROLIMUS; URSODEOXYCHOLIC ACID; VANCOMYCIN; VITAMIN D;

ABDOMINAL PAIN; ARTICLE; AUTOIMMUNE HEPATITIS; BILE DUCT; BILE DUCT CANCER; BILE DUCT CARCINOMA; CANCER RISK; CAUSE OF DEATH; CELIAC DISEASE; CHILL; CHOLANGIOGRAPHY; CHRONIC INFLAMMATION; CHRONIC PANCREATITIS; COLORECTAL CANCER; DECOMPENSATED LIVER CIRRHOSIS; DISEASE ASSOCIATION; ENDOSCOPIC THERAPY; ENTERITIS; FATIGUE; FEVER; FIBROSIS; GALLBLADDER CANCER; GENDER; HEPATOJEJUNOSTOMY; HEREDITY; IMMUNOGLOBULIN G4 RELATED DISEASE; JAUNDICE; LIVER FAILURE; LIVER INJURY; LIVER TRANSPLANTATION; MALABSORPTION; METABOLIC BONE DISEASE; MIDDLE AGED; OSTEOPENIA; OSTEOPOROSIS; PANCREAS CANCER; PATHOGENESIS; PERCUTANEOUS TRANSHEPATIC CHOLANGIOGRAPHY; PORTAL HYPERTENSION; PRIMARY SCLEROSING CHOLANGITIS; PROGNOSIS; PRURITUS; RISK ASSESSMENT; SCLEROSING CHOLANGITIS; UPPER ABDOMINAL PAIN; VITAMIN DEFICIENCY; VITAMIN SUPPLEMENTATION; WEIGHT REDUCTION;

AIH; AUTOIMMUNE HEPATITIS; CA19-9; CARBOHYDRATE ANTIGEN 19-9; CCA; CHOLANGIOCARCINOMA; COLORECTAL CANCER; CRC; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; ERCP; FISH; FLUORESCENCE IN SITU HYBRIDIZATION; IBD; INFLAMMATORY BOWEL DISEASE; LIVER TRANSPLANTATION; LT; MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY; MRCP; PRIMARY SCLEROSING CHOLANGITIS; PRIMARY SCLEROSING CHOLANGITIS (PSC); PSC; UC; UDCA; ULCERATIVE COLITIS; URSODEOXYCHOLIC ACID;

BILE DUCTS; CHOLANGIOCARCINOMA; CHOLANGITIS, SCLEROSING; GALLBLADDER NEOPLASMS; HUMANS; HYPERTENSION, PORTAL; LIVER FAILURE; LIVER NEOPLASMS; LIVER TRANSPLANTATION; PROGNOSIS;

EID: 84880580928     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2013.02.016     Document Type: Article

References (108)

1. Bambha K., Kim W.R., Talwalkar J., et al. Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology 2003, 125:1364-1369.
2. Broomé U., Olsson R., Lööf L., et al. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut 1996, 38:610-615.
3. Farrant J.M., Hayllar K.M., Wilkinson M.L., et al. Natural history and prognostic variables in primary sclerosing cholangitis. Gastroenterology 1991, 100:1710-1717.
4. Kingham J.G., Kochar N., Gravenor M.B. Incidence, clinical patterns, and outcomes of primary sclerosing cholangitis in south Wales, United Kingdom. Gastroenterology 2004, 126:1929-1930.
5. Ponsioen C.Y., Vrouenraets S.M., Prawirodirdjo W., et al. Natural history of primary sclerosing cholangitis and prognostic value of cholangiography in a Dutch population. Gut 2002, 51:562-566.
6. Tischendorf J.J., Hecker H., Krüger M., et al. Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: a single center study. Am J Gastroenterol 2007, 102:107-114.
7. Wiesner R.H., Grambsch P.M., Dickson E.R., et al. Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis. Hepatology 1989, 10:430-436.
8. Bergquist A., Ekbom A., Olsson R., et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol 2002, 36:321-327.
9. Molodecky N.A., Kareemi H., Parab R., et al. Incidence of primary sclerosing cholangitis: a systematic review and meta-analysis. Hepatology 2011, 53:1590-1599.
10. Boberg K.M., Aadland E., Jahnsen J., et al. Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. Scand J Gastroenterol 1998, 33:99-103.
11. Karlsen T.H. The Nordic liver transplant registry. Annu Rep 2009, 2012:2009.
12. Kaplan G.G., Laupland K.B., Butzner D., et al. The burden of large and small duct primary sclerosing cholangitis in adults and children: a population-based analysis. Am J Gastroenterol 2007, 102:1042-1049.
13. Loftus E.V., Sandborn W.J., Tremaine W.J., et al. Primary sclerosing cholangitis is associated with nonsmoking: a case-control study. Gastroenterology 1996, 110:1496-1502.
14. Mitchell S.A., Thyssen M., Orchard T.R., et al. Cigarette smoking, appendectomy, and tonsillectomy as risk factors for the development of primary sclerosing cholangitis: a case control study. Gut 2002, 51:567-573.
15. van Erpecum K.J., Smits S.J., van de Meeberg P.C., et al. Risk of primary sclerosing cholangitis is associated with nonsmoking behavior. Gastroenterology 1996, 110:1503-1506.
16. Pollheimer M.J., Halilbasic E., Fickert P., et al. Pathogenesis of primary sclerosing cholangitis. Best Pract Res Clin Gastroenterol 2011, 25:727-739.
17. Bergquist A., Lindberg G., Saarinen S., et al. Increased prevalence of primary sclerosing cholangitis among first-degree relatives. J Hepatol 2005, 42:252-256.
18. Karlsen T.H., Franke A., Melum E., et al. Genome-wide association analysis in primary sclerosing cholangitis. Gastroenterology 2010, 138:1102-1111.
19. Yang X., Cullen S.N., Li J.H., et al. Susceptibility to primary sclerosing cholangitis is associated with polymorphisms of intercellular adhesion molecule-1. J Hepatol 2004, 40:375-379.
20. Mitchell S.A., Grove J., Spurkland A., et al. Association of the tumour necrosis factor alpha -308 but not the interleukin 10 -627 promoter polymorphism with genetic susceptibility to primary sclerosing cholangitis. Gut 2001, 49:288-294.
21. Satsangi J., Chapman R.W., Haldar N., et al. A functional polymorphism of the stromelysin gene (MMP-3) influences susceptibility to primary sclerosing cholangitis. Gastroenterology 2001, 121:124-130.
22. O'Mahony C.A., Vierling J.M. Etiopathogenesis of primary sclerosing cholangitis. Semin Liver Dis 2006, 26:3-21.
23. Grant A.J., Lalor P.F., Salmi M., et al. Homing of mucosal lymphocytes to the liver in the pathogenesis of hepatic complications of inflammatory bowel disease. Lancet 2002, 359:150-157.
24. Fosby B., Karlsen T.H., Melum E. Recurrence and rejection in liver transplantation for primary sclerosing cholangitis. World J Gastroenterol 2012, 18:1-15.
25. Terjung B., Söhne J., Lechtenberg B., et al. p-ANCAs in autoimmune liver disorders recognise human beta-tubulin isotype 5 and cross-react with microbial protein FtsZ. Gut 2010, 59:808-816.
26. Fickert P., Fuchsbichler A., Wagner M., et al. Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology 2004, 127:261-274.
27. Okolicsanyi L., Fabris L., Viaggi S., et al. Primary sclerosing cholangitis: clinical presentation, natural history and prognostic variables: an Italian multicentre study. The Italian PSC Study Group. Eur J Gastroenterol Hepatol 1996, 8:685-691.
28. Porayko M.K., Wiesner R.H., LaRusso N.F., et al. Patients with asymptomatic primary sclerosing cholangitis frequently have progressive disease. Gastroenterology 1990, 98:1594-1602.
29. Chapman R., Fevery J., Kalloo A., et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology 2010, 51:660-678.
30. Talwalkar J.A., Lindor K.D. Primary sclerosing cholangitis. Inflamm Bowel Dis 2005, 11:62-72.
31. Wiesner R.H., LaRusso N.F. Clinicopathologic features of the syndrome of primary sclerosing cholangitis. Gastroenterology 1980, 79:200-206.
32. Angulo P., Peter J.B., Gershwin M.E., et al. Serum autoantibodies in patients with primary sclerosing cholangitis. J Hepatol 2000, 32:182-187.
33. Mulder A.H., Horst G., Haagsma E.B., et al. Prevalence and characterization of neutrophil cytoplasmic antibodies in autoimmune liver diseases. Hepatology 1993, 17:411-417.
34. Bansi D.S., Fleming K.A., Chapman R.W. Importance of antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis and ulcerative colitis: prevalence, titre, and IgG subclass. Gut 1996, 38:384-389.
35. MacCarty R.L., LaRusso N.F., Wiesner R.H., et al. Primary sclerosing cholangitis: findings on cholangiography and pancreatography. Radiology 1983, 149:39-44.
36. Textor H.J., Flacke S., Pauleit D., et al. Three-dimensional magnetic resonance cholangiopancreatography with respiratory triggering in the diagnosis of primary sclerosing cholangitis: comparison with endoscopic retrograde cholangiography. Endoscopy 2002, 34:984-990.
37. Angulo P., Pearce D.H., Johnson C.D., et al. Magnetic resonance cholangiography in patients with biliary disease: its role in primary sclerosing cholangitis. J Hepatol 2000, 33:520-527.
38. Berstad A.E., Aabakken L., Smith H.J., et al. Diagnostic accuracy of magnetic resonance and endoscopic retrograde cholangiography in primary sclerosing cholangitis. Clin Gastroenterol Hepatol 2006, 4:514-520.
39. Talwalkar J.A., Angulo P., Johnson C.D., et al. Cost-minimization analysis of MRC versus ERCP for the diagnosis of primary sclerosing cholangitis. Hepatology 2004, 40:39-45.
40. Bangarulingam S.Y., Gossard A.A., Petersen B.T., et al. Complications of endoscopic retrograde cholangiopancreatography in primary sclerosing cholangitis. Am J Gastroenterol 2009, 104:855-860.
41. Ludwig J. Surgical pathology of the syndrome of primary sclerosing cholangitis. Am J Surg Pathol 1989, 13(Suppl 1):43-49.
42. Burak K.W., Angulo P., Lindor K.D. Is there a role for liver biopsy in primary sclerosing cholangitis?. Am J Gastroenterol 2003, 98:1155-1158.
43. Ludwig J., Barham S.S., LaRusso N.F., et al. Morphologic features of chronic hepatitis associated with primary sclerosing cholangitis and chronic ulcerative colitis. Hepatology 1981, 1:632-640.
44. Corpechot C., El Naggar A., Poujol-Robert A., et al. Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC. Hepatology 2006, 43:1118-1124.
45. Mendes F., Lindor K.D. Primary sclerosing cholangitis: overview and update. Nat Rev Gastroenterol Hepatol 2010, 7:611-619.
46. Björnsson E., Olsson R., Bergquist A., et al. The natural history of small-duct primary sclerosing cholangitis. Gastroenterology 2008, 134:975-980.
47. Björnsson E. Small-duct primary sclerosing cholangitis. Curr Gastroenterol Rep 2009, 11:37-41.
48. Davit-Spraul A., Gonzales E., Baussan C., et al. The spectrum of liver diseases related to ABCB4 gene mutations: pathophysiology and clinical aspects. Semin Liver Dis 2010, 30:134-146.
49. Kaya M., Angulo P., Lindor K.D. Overlap of autoimmune hepatitis and primary sclerosing cholangitis: an evaluation of a modified scoring system. J Hepatol 2000, 33:537-542.
50. Floreani A., Rizzotto E.R., Ferrara F., et al. Clinical course and outcome of autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome. Am J Gastroenterol 2005, 100:1516-1522.
51. Beuers U., Rust C. Overlap syndromes. Semin Liver Dis 2005, 25:311-320.
52. Björnsson E., Chari S.T., Smyrk T.C., et al. Immunoglobulin G4 associated cholangitis: description of an emerging clinical entity based on review of the literature. Hepatology 2007, 45:1547-1554.
53. Ghazale A., Chari S.T., Zhang L., et al. Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. Gastroenterology 2008, 134:706-715.
54. Mendes F.D., Jorgensen R., Keach J., et al. Elevated serum IgG4 concentration in patients with primary sclerosing cholangitis. Am J Gastroenterol 2006, 101:2070-2075.
55. Burak K., Angulo P., Pasha T.M., et al. Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol 2004, 99:523-526.
56. Kornfeld D., Ekbom A., Ihre T. Survival and risk of cholangiocarcinoma in patients with primary sclerosing cholangitis. A population-based study. Scand J Gastroenterol 1997, 32:1042-1045.
57. Razumilava N., Gores G.J., Lindor K.D. Cancer surveillance in patients with primary sclerosing cholangitis. Hepatology 2011, 54:1842-1852.
58. Claessen M.M., Vleggaar F.P., Tytgat K.M., et al. High lifetime risk of cancer in primary sclerosing cholangitis. J Hepatol 2009, 50:158-164.
59. Charatcharoenwitthaya P., Enders F.B., Halling K.C., et al. Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis. Hepatology 2008, 48:1106-1117.
60. Moreno Luna L.E., Kipp B., Halling K.C., et al. Advanced cytologic techniques for the detection of malignant pancreatobiliary strictures. Gastroenterology 2006, 131:1064-1072.
61. Boonstra K., Beuers U., Ponsioen C.Y. Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review. J Hepatol 2012, 56:1181-1188.
62. Loftus E.V., Harewood G.C., Loftus C.G., et al. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut 2005, 54:91-96.
63. Joo M., Abreu-e-Lima P., Farraye F., et al. Pathologic features of ulcerative colitis in patients with primary sclerosing cholangitis: a case-control study. Am J Surg Pathol 2009, 33:854-862.
64. O'Toole A., Alakkari A., Keegan D., et al. Primary sclerosing cholangitis and disease distribution in inflammatory bowel disease. Clin Gastroenterol Hepatol 2012, 10:439-441.
65. Sokol H., Cosnes J., Chazouilleres O., et al. Disease activity and cancer risk in inflammatory bowel disease associated with primary sclerosing cholangitis. World J Gastroenterol 2008, 14:3497-3503.
66. Hagness M., Foss A., Line P.D., et al. Liver transplantation for non-resectable liver metastases from colorectal cancer. Liver Transplant 2012, 18:S140.
67. Halliday J.S., Djordjevic J., Lust M., et al. A unique clinical phenotype of primary sclerosing cholangitis associated with Crohn's disease. J Crohns Colitis 2012, 6:174-181.
68. Fleshner P.R., Vasiliauskas E.A., Kam L.Y., et al. High level perinuclear antineutrophil cytoplasmic antibody (pANCA) in ulcerative colitis patients before colectomy predicts the development of chronic pouchitis after ileal pouch-anal anastomosis. Gut 2001, 49:671-677.
69. Lepistö A., Kärkkäinen P., Järvinen H.J. Prevalence of primary sclerosing cholangitis in ulcerative colitis patients undergoing proctocolectomy and ileal pouch-anal anastomosis. Inflamm Bowel Dis 2008, 14:775-779.
70. Wiesner R.H., LaRusso N.F., Dozois R.R., et al. Peristomal varices after proctocolectomy in patients with primary sclerosing cholangitis. Gastroenterology 1986, 90:316-322.
71. Soetikno R.M., Lin O.S., Heidenreich P.A., et al. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc 2002, 56:48-54.
72. Farraye F.A., Odze R.D., Eaden J., et al. AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology 2010, 138:738-745.
73. Thackeray E.W., Charatcharoenwitthaya P., Elfaki D., et al. Colon neoplasms develop early in the course of inflammatory bowel disease and primary sclerosing cholangitis. Clin Gastroenterol Hepatol 2011, 9:52-56.
74. Brandt D.J., MacCarty R.L., Charboneau J.W., et al. Gallbladder disease in patients with primary sclerosing cholangitis. AJR Am J Roentgenol 1988, 150:571-574.
75. Said K., Glaumann H., Bergquist A. Gallbladder disease in patients with primary sclerosing cholangitis. J Hepatol 2008, 48:598-605.
76. Lewis J.T., Talwalkar J.A., Rosen C.B., et al. Prevalence and risk factors for gallbladder neoplasia in patients with primary sclerosing cholangitis: evidence for a metaplasia-dysplasia-carcinoma sequence. Am J Surg Pathol 2007, 31:907-913.
77. Eaton J.E., Thackeray E.W., Lindor K.D. Likelihood of malignancy in gallbladder polyps and outcomes following cholecystectomy in primary sclerosing cholangitis. Am J Gastroenterol 2012, 107:431-439.
78. Bunchorntavakul C., Reddy K.R. Pruritus in chronic cholestatic liver disease. Clin Liver Dis 2012, 16:331-346.
79. EASL Clinical Practice guidelines: management of cholestatic liver diseases. J Hepatol 2009, 51:237-267. European Association for the Study of the Liver.
80. Angulo P., Grandison G.A., Fong D.G., et al. Bone disease in patients with primary sclerosing cholangitis. Gastroenterology 2011, 140:180-188.
81. Guichelaar M.M., Kendall R., Malinchoc M., et al. Bone mineral density before and after OLT: long-term follow-up and predictive factors. Liver Transpl 2006, 12:1390-1402.
82. Jorgensen R.A., Lindor K.D., Sartin J.S., et al. Serum lipid and fat-soluble vitamin levels in primary sclerosing cholangitis. J Clin Gastroenterol 1995, 20:215-219.
83. Abraham S.C., Kamath P.S., Eghtesad B., et al. Liver transplantation in precirrhotic biliary tract disease: portal hypertension is frequently associated with nodular regenerative hyperplasia and obliterative portal venopathy. Am J Surg Pathol 2006, 30:1454-1461.
84. Culver E.L., Chapman R.W. Systematic review: management options for primary sclerosing cholangitis and its variant forms - IgG4-associated cholangitis and overlap with autoimmune hepatitis. Aliment Pharmacol Ther 2011, 33:1273-1291.
85. Lindor K.D. Ursodiol for primary sclerosing cholangitis. Mayo primary sclerosing cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med 1997, 336:691-695.
86. Lindor K.D., Kowdley K.V., Luketic V.A., et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology 2009, 50:808-814.
87. Triantos C.K., Koukias N.M., Nikolopoulou V.N., et al. Meta-analysis: ursodeoxycholic acid for primary sclerosing cholangitis. Aliment Pharmacol Ther 2011, 34:901-910.
88. Halilbasic E., Fiorotto R., Fickert P., et al. Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2-/- mice. Hepatology 2009, 49:1972-1981.
89. Tung B.Y., Emond M.J., Haggitt R.C., et al. Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med 2001, 134:89-95.
90. Pardi D.S., Loftus E.V., Kremers W.K., et al. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 2003, 124:889-893.
91. Eaton J.E., Silveira M.G., Pardi D.S., et al. High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Am J Gastroenterol 2011, 106:1638-1645.
92. Singh S., Pardi D.S., Loftus E.V., et al. Ursodeoxycholic acid and risk of colorectal neoplasia in patients with primary sclerosing cholangitis: a meta-analysis. Inflamm Bowel Dis 2012, 18:S29.
93. Kaya M., Petersen B.T., Angulo P., et al. Balloon dilation compared to stenting of dominant strictures in primary sclerosing cholangitis. Am J Gastroenterol 2001, 96:1059-1066.
94. Johnson G.K., Geenen J.E., Venu R.P., et al. Endoscopic treatment of biliary tract strictures in sclerosing cholangitis: a larger series and recommendations for treatment. Gastrointest Endosc 1991, 37:38-43.
95. Cameron J.L., Pitt H.A., Zinner M.J., et al. Resection of hepatic duct bifurcation and transhepatic stenting for sclerosing cholangitis. Ann Surg 1988, 207:614-622.
96. Myburgh J.A. Surgical biliary drainage in primary sclerosing cholangitis. The role of the Hepp-Couinaud approach. Arch Surg 1994, 129:1057-1062.
97. Baluyut A.R., Sherman S., Lehman G.A., et al. Impact of endoscopic therapy on the survival of patients with primary sclerosing cholangitis. Gastrointest Endosc 2001, 53:308-312.
98. Graziadei I.W., Wiesner R.H., Marotta P.J., et al. Long-term results of patients undergoing liver transplantation for primary sclerosing cholangitis. Hepatology 1999, 30:1121-1127.
99. Darwish Murad S., Kim W.R., Harnois D.M., et al. Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology 2012, 143:88-98 e3. quiz e14.
100. Egawa H., Taira K., Teramukai S., et al. Risk factors for recurrence of primary sclerosing cholangitis after living donor liver transplantation: a single center experience. Dig Dis Sci 2009, 54:1347-1354.
101. Graziadei I.W., Wiesner R.H., Batts K.P., et al. Recurrence of primary sclerosing cholangitis following liver transplantation. Hepatology 1999, 29:1050-1056.
102. Alabraba E., Nightingale P., Gunson B., et al. A re-evaluation of the risk factors for the recurrence of primary sclerosing cholangitis in liver allografts. Liver Transpl 2009, 15:330-340.
103. Haagsma E.B., Van Den Berg A.P., Kleibeuker J.H., et al. Inflammatory bowel disease after liver transplantation: the effect of different immunosuppressive regimens. Aliment Pharmacol Ther 2003, 18:33-44.
104. Verdonk R.C., Dijkstra G., Haagsma E.B., et al. Inflammatory bowel disease after liver transplantation: risk factors for recurrence and de novo disease. Am J Transplant 2006, 6:1422-1429.
105. LaRusso N.F., Shneider B.L., Black D., et al. Primary sclerosing cholangitis: summary of a workshop. Hepatology 2006, 44:746-764.
106. Dickson E.R., Murtaugh P.A., Wiesner R.H., et al. Primary sclerosing cholangitis: refinement and validation of survival models. Gastroenterology 1992, 103:1893-1901.
107. Kim W.R., Therneau T.M., Wiesner R.H., et al. A revised natural history model for primary sclerosing cholangitis. Mayo Clin Proc 2000, 75:688-694.
108. Rudolph G., Gotthardt D., Klöters-Plachky P., et al. Influence of dominant bile duct stenoses and biliary infections on outcome in primary sclerosing cholangitis. J Hepatol 2009, 51:149-155.